JPMorgan Chase & Co. Has $6.90 Million Position in Sera Prognostics, Inc. (NASDAQ:SERA)

JPMorgan Chase & Co. boosted its stake in shares of Sera Prognostics, Inc. (NASDAQ:SERA) by 7,357.8% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 884,867 shares of the company’s stock after purchasing an additional 873,002 shares during the quarter. JPMorgan Chase & Co. owned about 2.62% of Sera Prognostics worth $6,902,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Quest Partners LLC grew its stake in Sera Prognostics by 533.5% in the 3rd quarter. Quest Partners LLC now owns 6,430 shares of the company’s stock valued at $50,000 after buying an additional 5,415 shares during the last quarter. The Manufacturers Life Insurance Company bought a new stake in Sera Prognostics during the second quarter valued at about $68,000. SG Americas Securities LLC acquired a new stake in shares of Sera Prognostics in the third quarter valued at about $78,000. Prime Capital Investment Advisors LLC bought a new position in shares of Sera Prognostics in the third quarter worth about $104,000. Finally, Jane Street Group LLC lifted its position in shares of Sera Prognostics by 24.8% during the 3rd quarter. Jane Street Group LLC now owns 14,225 shares of the company’s stock worth $111,000 after purchasing an additional 2,826 shares during the last quarter. Institutional investors and hedge funds own 54.64% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Zhenya Lindgardt sold 12,075 shares of Sera Prognostics stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $7.32, for a total transaction of $88,389.00. Following the sale, the chief executive officer now owns 819,758 shares of the company’s stock, valued at approximately $6,000,628.56. This trade represents a 1.45 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, General Counsel Benjamin Jackson sold 4,727 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $7.32, for a total value of $34,601.64. Following the sale, the general counsel now owns 135,528 shares in the company, valued at approximately $992,064.96. This represents a 3.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 93,215 shares of company stock worth $666,835 in the last ninety days. Insiders own 15.80% of the company’s stock.

Sera Prognostics Stock Up 3.8 %

Shares of NASDAQ:SERA opened at $6.61 on Thursday. The company has a market cap of $223.23 million, a price-to-earnings ratio of -6.68 and a beta of 0.86. The business has a 50 day moving average price of $7.44 and a 200 day moving average price of $7.31. Sera Prognostics, Inc. has a twelve month low of $4.98 and a twelve month high of $12.35.

Sera Prognostics (NASDAQ:SERA) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.02). The firm had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.09 million. During the same period last year, the company earned ($0.23) earnings per share. Analysts anticipate that Sera Prognostics, Inc. will post -0.96 EPS for the current year.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.